Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168077 | 0.92 | HIF1A (0.45) | HIF1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23965620 | 0.92 | HIF1A (0.45) | HIF1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28917435 | 0.89 | NPC1 (0.37) | HIF1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25224343 | 0.89 | NPC1 (0.37) | HIF1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30214721 | 0.86 | HIF1A (0.41) | HIF1AGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23965621 | 0.86 | ALDH1A1 (0.38) | HIF1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23965569 | 0.86 | GAA (0.36) | HIF1AGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30168064 | 0.86 | GAA (0.36) | HIF1AGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23971859 | 0.84 | HIF1A (0.42) | HIF1ANPC1SMN1; SMN2PKM | |
| SCHEMBL23971854 | 0.83 | HIF1A (0.43) | HIF1ANPC1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142496-B1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS (IV) | BASF SE (DE) | 2025-07-30 | — | — | EP | disclosed |
| EP-4142494-B1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS (II) | BASF SE (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4142495-B1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS (III) | BASF SE (DE) | 2025-07-09 | — | — | EP | disclosed |
| EP-4142497-B1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS (I) | BASF SE (DE) | 2025-07-09 | — | — | EP | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230172207-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS I | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172206-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172204-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2023072670-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS X | BASF SE (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023072672-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XI | BASF SE (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023072671-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IX | BASF SE (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4142496-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142494-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142497-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS I | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142495-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| CN-115460919-A | Use of strobilurin-type compounds to control phytopathogenic fungi containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring tolerance to Qo inhibitors IV | 巴斯夫欧洲公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172204-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | COX5B, SQOR, UQCRB | HIF1A 2044/4885GAA 1713/4885KDM4E 3645/4885 |
| US-20230172207-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS I | COX5B, SQOR, UQCRB | HIF1A 1889/4885GAA 1761/4885KDM4E 3624/4885 |
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | COX5B, SQOR, COX5A | HIF1A 2001/4885GAA 1785/4885KDM4E 2889/4885 |
| US-20230172206-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II | COX5B, SQOR, UQCRB | HIF1A 2078/4885GAA 1770/4885KDM4E 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.